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To the Editor: Vadivel et al.1 discussed the evaluation of a
living kidney donor candidate with isolated microhematuria.
The volunteer had a normal serum creatinine, no proteinuria,
thin basement membrane disease, and IgA nephropathy.
The risk was said to be unknown and she was therefore
excluded from donating. We think this was a mistake.
All living kidney donors face risk. To make informed
decisions, potential donors and centers must have some idea
of the risk involved. We agree that we must never go ‘shooting
in the dark’. However, while we may not know the precise risk
involved, often we can provide a reasonable estimate.
In the case presented, risk can be approximated from
cohort studies of isolated microhematuria in the general
population and the incidence of end-stage renal disease
associated with this condition. The estimated 20-year risk of
end-stage renal disease for this woman is less than 1% and
there is little evidence that uninephrectomy would change
this.2 Had she understood this information, donation would
have been a reasonable option.
Risk evaluation is essential to defensible living kidney
donor selection practices,3 especially for volunteers with
minor medical abnormalities that increase the risk of
donating, some of whom may still be acceptable. So, before
we jump to say no, we should first estimate the risk of
donating. Unless the risk is very high, we should present that
information to the volunteer. Given that the reasonableness
of donating depends on individual as well as center values, it
is always important to consider the volunteer’s point of view
as we assess the situation.4
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Dr Steiner and Spital1 disagree with our recommendation
that a potential kidney donor who has hematuria and
biopsy evidence of IgA nephropathy and thin basement
membrane disease should be declined the opportunity of
donation.2 We continue to hold to this recommendation.
Currently, there is no long-term outcome data on the
actual risk of kidney donation in individuals with this risk
profile. On the other hand, there is evidence that some of
these patients with IgA nephropathy and/or thin basement
membrane disease progress to kidney failure. The natural
history of patients diagnosed with IgA nephropathy reveals
that 15–40% of these patients may proceed to end-stage
renal disease.3 Although we agree that patients are more
likely to have additional risk features, such as macroscopic
hematuria or hypertension or proteinuria, this may not
always be the case. Indeed, Koselj et al.4observed three
living related kidney donors with silent IgA nephropathy
for 7 years. While two of these donors had no clinically
significant renal disease over 7 years of follow-up, the third
donor developed progressive renal insufficiency. These
findings strongly argue against kidney donation if biopsy
evidence of IgA deposition is found. Similarly, patients
with evidence of thin basement membrane disease may
also progress to kidney failure, although this occurs in a
minority of patients.5,6
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